Herantis Pharma logo
Search
  • About Us
    • Company profile
    • Team
    • Board of Directors
    • Nomination Committee
    • Scientific Advisory Board
  • Pipeline
    • Pipeline overview
    • CDNF
    • Next generation xCDNF
    • Lymfactin®
    • Scientific publications
  • Investors
    • Investors
    • Releases
    • Analyst Coverage
    • Financial Calendar
    • General Meetings
    • Financial Information
    • Share Information
    • Major Shareholders
    • Share Monitor
    • Investor Relations
    • Corporate Governance
  • News & Events
    • Herantis in the News
    • Events
    • Releases
    • Public materials
    • Video Presentations
    • Newsletter
  • Patients
    • Overview & Contact Us
    • Parkinson’s Disease
    • Lymphedema
    • Community Resources
  • Contact
  • FIN
Search

Latest releases

  • CDNF releases
  • Earnings Release
  • First north
  • General releases
  • Insider trading
  • Lymfactin releases
  • Newsletter
  • Press Release
  • Clear
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 29.03.2021
    Herantis Pharma to focus on CDNF and xCDNF programs
  • 25.03.2021
    FN, GR
    Herantis Pharma Published the Annual Report for the Financial Year 2020
  • 23.03.2021
    FN, GR
    NOTICE TO CONVENE HERANTIS PHARMA PLC’S ANNUAL GENERAL MEETING OF SHAREHOLDERS
  • 11.03.2021
    CR, PR
    Herantis Pharma Announces an Oral Presentation and a Poster Presentation related to First-in-Man CDNF Clinical Trial at AD/PD™ Virtual Conference
  • 09.03.2021
    Proposals of the Shareholders’ Nomination Committee to Herantis Pharma Plc’s Annual General Meeting 2021
  • 04.03.2021
    PR
    Herantis Pharma to Participate in Three Upcoming Virtual Investor Conferences
  • 03.03.2021
    FN, GR
    Herantis Pharma Full Year Report 2020
  • 02.03.2021
    LR, PR
    Herantis Announces Inconclusive Results from Phase II Study with Lymfactin in Breast Cancer Related Lymphedema ®
  • 09.02.2021
    PR
    Herantis Pharma and Nanoform Enter into Agreement for Proof of Concept Collaboration
  • 08.02.2021
    PR
    Herantis Pharma to Participate in the Upcoming Swiss Nordic Bio Conference
  • « Previous page
  • Page 1
  • Page 2
  • Next page »

Quick links

Herantis in the News »
Events »
Releases »
Public materials »
Video Presentations »
Newsletter »
Herantis Pharma logo

HERANTIS PHARMA Plc
Bertel Jungin Aukio 1
FIN-02600 Espoo dsfs

Tel: +358 9 222 1195
Email: info (at) herantis.com
VAT number FI21986657

  • Legal notice
  • Privacy notice
  • Sign up for our bi-monthly newsletter

Copyright © HERANTIS PHARMA Plc. All rights reserved.

Cookies
This website uses cookies and Google Analytics. We use cookies and Google Analytics to adapt the website according to your preferences and to collect information about the use of the website. For more information regarding cookies we request you to review our privacy notice. The following terms and conditions are applied to the use of this website. By continuing to use this website you accept such terms and conditions.
OK
Privacy notice
Legal notice
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT